Skip to main content
TipRanks
Go Ultimate75% OFF

PhoenixBio Co., Ltd. (6190) AI Stock Analysis

0 Followers
JP:6190

PhoenixBio Co., Ltd.

(TSE/TYO:6190)

Select Model
Rating:54Neutral
Price Target:JPY 254.00â–²(2.01% Upside)
Action:reiterated
Date:10/16/26

PhoenixBio's overall score is significantly weighed down by an expensive valuation profile and a clear bearish technical trend. While the company's financial fundamentals show an encouraging turnaround with a strong, deleveraged balance sheet, the exceptionally high P/E ratio and weak price momentum present notable near-term risks.

Positive Factors
Strong Gross MarginA gross margin near 76% indicates PhoenixBio retains substantial value from its specialized preclinical services and humanized-liver mouse models. If maintained, this profitability buffer can support research investment, customer support, and resilience as the company works to stabilize earnings.
Negative Factors
Volatile Earnings HistoryThe wide swings between losses and profits make the recent recovery less proven as a durable earnings trend. Such volatility can complicate planning, limit confidence in recurring operating performance, and make it harder for PhoenixBio to sustain investment through a full business cycle.

PhoenixBio Co., Ltd. (6190) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%60%JP:6190-41.00%EWJ+11.03%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 936.15M
Dividend Yield
―
Average Volume (3M)
9,928
Price to Earnings (P/E)
-90.4
Beta (1Y)
0.58
Revenue Growth
-9.37%
EPS Growth
96.61%
Country
Japan
Employees
55
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

PhoenixBio Co., Ltd. Business Overview & Revenue Model

Company Description

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featurin...

PhoenixBio Co., Ltd. Financial Statement Overview

Summary

PhoenixBio demonstrates a strong balance sheet with successful deleveraging and a recent return to profitability and positive cash flow. However, historical volatility in revenue and earnings tempers its overall financial stability.

Income Statement

58Neutral

Balance Sheet

82Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.57B1.57B1.54B1.72B2.12B1.32B
Gross Profit1.20B1.19B1.11B1.20B1.56B727.79M
EBITDA129.60M116.52M-396.12M87.94M537.42M-305.81M
Net Income125.23M125.23M-445.65M26.38M493.33M-387.97M
Balance Sheet
Total Assets2.19B2.19B2.31B2.74B3.02B2.28B
Cash, Cash Equivalents and Short-Term Investments1.15B1.15B1.15B1.39B1.56B1.33B
Total Debt486.64M486.64M565.36M723.93M1.13B1.04B
Total Liabilities640.05M640.05M944.82M946.58M1.50B1.45B
Stockholders Equity1.55B1.55B1.37B1.80B1.51B828.15M
Cash Flow
Free Cash Flow056.42M-94.24M-118.08M265.12M9.63M
Operating Cash Flow068.86M-73.00M-79.31M277.49M16.40M
Investing Cash Flow0-13.75M-27.98M115.36M-156.34M-6.97M
Financing Cash Flow0-88.01M-128.00M-244.88M86.63M-34.66M

PhoenixBio Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price249.00

Price Trends

50DMA295.12Negative
100DMA318.88Negative
200DMA380.69Negative

Market Momentum

MACD-15.61Negative
RSI33.21Neutral
STOCH40.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6190, the sentiment is Negative. The current price of 249.00 is below the 20-day moving average (MA) of 268.95, below the 50-day MA of 295.12, and below the 200-day MA of 380.69, indicating a bearish trend. The MACD of -15.61 indicates Negative momentum. The RSI at 33.21 is Neutral, neither overbought nor oversold. The STOCH value of 40.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6190.

PhoenixBio Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:6190 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6190JP:619054NeutralJPY 1.02B-90.42――-9.37%96.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497845NeutralJPY 11.75B-24.37――-8.23%-48.10%
JP:2342JP:234244NeutralJPY 3.02B-156.08――8.53%97.93%
JP:7774JP:777442NeutralJPY 26.03B-70.96――17.05%10.47%
JP:7776JP:777637UnderperformJPY 6.07B-4.74――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

0%50%100%JP:6190JP:2342JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:6190 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:6190PhoenixBio Co., Ltd.249.00-173.00-41.00%
JP:2342Trans Genic Inc.179.00-49.00-21.49%
JP:4978ReproCELL Inc.110.00-45.00-29.03%
JP:7774Japan Tissue Engineering Co., Ltd.641.00155.0031.89%
JP:7776CellSeed Inc.153.00-141.00-47.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026